November 16, 2026
Source: drugdu
36

On November 16, SSY Group (02005) announced that it had renewed reimbursement coverage for stiripentol powder for oral suspension. The product remains on China’s 2026 National Reimbursement Drug List.
The product was approved in 2023 as China’s first generic stiripentol and comes in 250 mg and 500 mg strengths. It is used primarily to treat Dravet syndrome, also known as severe myoclonic epilepsy of infancy. China included the syndrome in its first rare disease list in 2018.
Source: http://finance.eastmoney.com/a/202611163931669467.html
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.